ELUT — ELUTIA INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1708527 ·
Last close
$0.81
Market Cap
$35.87M
52W High
$1.38
52W Low
$0.50
ADV30
46,491
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,427,000 | 1,447,000 | -5,900,000 | -7,646,000 | 43,649,000 | 19,896,000 | 27,903,000 |
| Mar 2026 | 3,114,000 | 1,802,000 | -5,742,000 | -7,469,000 | 55,209,000 | 28,488,000 | 32,682,000 |
| Dec 2025 | 3,271,000 | 1,914,000 | -5,491,000 | 70,791,000 | 62,350,000 | 36,350,000 | 34,678,000 |
| Sep 2025 | 3,323,000 | 1,853,000 | -4,355,000 | -3,868,000 | 29,407,000 | 4,721,000 | 73,325,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,760,000
Investing CF
$78,803,000
Financing CF
$-23,913,000
CapEx
$-2,057,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.86
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-183,682,000
Inventory
$2,657,000
Receivables
$15,416,000
ST Investments
—
EBIT TTM
$-20,427,000
Pretax Income TTM
$-24,322,000
Interest Exp TTM
$2,037,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,136,000
EBITDA
$-21,353,000
Free Cash Flow
$-27,474,000
Enterprise Value
$20,358,276
Total Cash
$19,896,000
Total Debt
$4,380,000
Shares Out
44,289,230
Trailing EPS
$-0.63
Book Value
$0.36
ROE
—
ROA
-34.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,293,000 | -18,412,000 | 53,380,000 | 62,350,000 | 34,678,000 | 27,672,000 | -44,810,000 |
| Dec 2024 | 14,467,000 | -19,344,000 | -53,949,000 | 36,127,000 | 82,387,000 | -46,260,000 | -22,657,000 |
| Dec 2023 | 24,745,000 | -20,537,000 | -37,656,000 | 43,428,000 | 82,028,000 | -38,600,000 | -21,761,000 |
| Dec 2022 | 23,849,000 | -29,989,000 | -32,897,000 | 68,841,000 | 73,874,000 | -5,033,000 | -21,434,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRML | Greenland Mines Ltd | $37.65M | $11.85 | — |
| GNTA | Genenta Science S.p.A. | $33.28M | $0.69 | — |
| SCLX | Scilex Holding Co | $31.59M | $4.49 | — |
| ALGS | Aligos Therapeutics, Inc. | $30.16M | $5.54 | — |
| CVM | CEL SCI CORP | $29.90M | $1.70 | — |
News headlines (Yahoo Finance, 1h cache)
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
2026-09-10 20:05 · Yahoo
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 20:05 · Yahoo
Elutia (ELUT) Q2 2026 Earnings Call Transcript
2026-08-20 20:58 · Yahoo
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
2026-08-18 12:00 · Yahoo
Elutia Inc. Q2 2026 Earnings Call Summary
2026-08-14 12:30 · Yahoo
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ...
2026-08-14 05:01 · Yahoo
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
2026-08-13 20:05 · Yahoo
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
2026-07-31 12:00 · Yahoo
Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio
2026-07-16 20:21 · Yahoo
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
2026-07-16 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.